RRCancer-Banque Cancers GynÃ©cologiques-LDI/JGH, Canada

Certification Status: Checklist Required

Registration Status: Completed

Objective: The rapid increase in global cancer represents a significant challenge for health systems worldwide. Cancer has now become the first cause of mortality in western countries, accounting for one third of all causes of death. Ovarian cancer (OC) is the deadliest of all gynecological cancers and 5th leading cause of cancer mortality in women. This cancer appears after a long latency with a mean age of incidence of ~58 years (1, 2) and early detection of the disease is non-existent. In studies with tissues or cells isolated from advanced stage OC, it has been difficult to segregate the changes related to disease initiation from other factors like progression and metastasis. The molecular pathways for early initiation or late progression of ovarian tumors are also unknown. The research community working on ovarian cancer in Canada is interested in a large scale, cooperative Canada-wide biomarker program

Registered Biobank Name	RRCancer-Banque Cancers GynÃ©cologiques-LDI/JGH
Biobank Leader	Amber Yasmeen
Country	Canada
Email for biobank inquiries	susie.lau@mcgill.ca
Principal Investigator	Susie Lau
Website
User Type Mono: A biobank that supports a specific research project, may have few staff members, a small-scale accrual scope with little to no initial intention of releasing or distributing biospecimens to secondary parties Oligo: A biobank that supports several research groups or clinical trials, may or may not be designed to release biospecimens outside their collaborative group Poly: A biobank that has generally a larger accrual scope, resources, and multiple users outside the biobank proper	Poly - Collection aimed at supporting undetermined, multiple users with ethics approved research projects, through a defined access/application mechanism.

Biospecimen Collected:

Cohort Highlights

100 cases Next Generation Sequencing assay to detect all classes of genetic variant in Lung Cancer using a single Diagnostic test.
200 cases Colorectal TMA for QC purposes in support of study of tumor infiltrating lymphocytes in ovarian cancer tissues.
Build 300 cases breast cancer TMA containing primary tumour and matched metastatic LN for various subtypes (luminal, HER2, Triple negative). Start with Triple negatives.
125 cases Breast tumour and metastatic lymph nodes in breast cancer cases with outcomes of metastasis to lung or bone.
100 cases of rare tumours - fibrolamellar hepatocellular carcinoma. FFPE, frozen, BC.
200 cases of FFPE tissue sections from breast, lung adenocarcinoma, and lung squamous cell carcinoma with matching normal tissue (only pathology data requested).